Monday - November 16, 2026
CUHK-developed novel peptide drug candidate granted FDA Orphan Drug Designation Offering new hope for Huntington's disease patients
September 23, 2026
SHATIN, Hong Kong, Sept. 23 -- The Chinese University of Hong Kong posted the following news release:

* * *

CUHK-developed novel peptide drug candidate granted FDA Orphan Drug Designation Offering new hope for Huntington's disease patients

*

A novel peptide drug candidate, jointly developed by the School of Life Sciences at The Chinese University of Hong Kong (CUHK) and its biotechnology spin-off company Rare Power Limited, has been grante . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Click here for more information about our products